Thanks for the show as always fella’s
Much appreciated.
Cbeers.

Segment 8:
A bit of collusion?!?
https://www.youtube.com/watch?v=cO0Lh8gOu5Q&feature=youtu.be

The whole deal stinks. Why would the US sell any uranium, so it is then necessary to IMPORT uranium?

Seg. 8: The NDA agreement (gag order) was lifted and testimony has been made.

Seg. 7:
http://www.washingtonexaminer.com/byron-york-what-explains-the-fbis-deep-faith-in-trump-dossier-author-christopher-steele/article/2648488

The Smearing of Christopher Steele
https://www.politico.com/magazine/story/2018/02/05/christopher-steele-dossier-smearing-216940

The Partisan Attacks on Christopher Steele
http://www.slate.com/articles/podcasts/trumpcast/2018/02/republican_efforts_to_smear_christopher_steele.html

Jacob Weisberg talks to John Sipher, a former senior member of the CIA, about Christopher Steele and the partisan attacks on him and his work.

Seg. 8:
https://legalinsurrection.com/2018/02/confirmed-clinton-operative-sidney-blumenthal-helped-spread-russia-collusion-fever-before-the-election/

Bitcoin News:
https://www.azcentral.com/story/money/business/tech/2018/02/09/bitcoin-tax-payments-arizona-could-become-first-state-u-s-allow/324424002/

Segment 4: Is there more behind the scenes, Cory, than we are being told about the economy?
http://beforeitsnews.com/politics/2018/02/trump-burns-opium-fields-so-elites-trash-markets-waa-2979961.html
SPECIAL REPORT: Stock Market Meltdown? Flash-crash? No. This Is What Happened. By Gregory Mannarino (https://www.youtube.com/watch?v=ETEBuIzxW4g)

‘Buy Gold!’ says the Bank of England

Adrian Ash – Bullion Vault – February 08th, 2018

“In effect it told UK investors and savers to buy gold. Because gold tends to rise when interest rates fail to rise faster than the cost of living.”

“And the Bank of England today confirmed it plans to stay way behind the curve on inflation…”

http://www.24hgold.com/english/news-gold-silver–buy-gold–says-the-bank-of-england.aspx?article=12366609448H11690

Paul Tudor Jones: “This Market Feels Like Japan In 1989 Or The US In 1999”

Fri, 02/09/2018

https://www.zerohedge.com/news/2018-02-08/paul-tudor-jones-market-feels-japan-1989-or-us-1999

Electric Cars and Niche Metals Lure Cash to Africa’s Mines
By Thomas Wilson and Thomas Biesheuvel – February 1, 2018

“The electric-vehicle boom and shifting industrial demand have transformed formerly niche metals — from lithium and cobalt to praseodymium and neodymium — into the hot new draw-cards of African mining.”

https://www.bloomberg.com/amp/news/articles/2018-02-02/electric-cars-and-niche-metals-lure-cash-back-to-african-mines

It’s A Mad, Mad, Mad World

Gary Wagner – February 9, 2018 #TechnicalAnalysis #VIDEO #Charts

https://thegoldforecast.com/video/it%E2%80%99s-mad-mad-mad-world

Dr. Stephen Leeb: I like the guy and believe him to be very bright but, he’s been wrong with his timing in the past. He seems to see macro advantages in China and with their silk road efforts that many others don’t even mention. https://kingworldnews.com/dr-stephen-leeb-2-10-18/

Meanwhile in the S. China Seas:

https://www.trunews.com/stream/china-puts-stealth-fighter-into-service

Seg. 6:

Some background information:

https://www.thenation.com/article/these-pharmaceutical-companies-are-making-a-killing-off-the-opioid-crisis/

On a side note, I listen to AGM meetings of many companies including Pharma.
I recall one company, a few weeks ago, mentioning that they will submit to WhiteHouse pressure to reduce production of opioids by 30% AND discontinue all freebies to M,D,s and stop support for sales.
I specifically remember at the time being shocked in that this is a clear violation of fiduciary responsibility of the CEO. (Even if it is the correct moral decision.)
I will try and dig out which company it was. (I must be getting old…memory failure.)

The Truth About the FISA Memo, With ex-CIA Analyst Ray McGovern

Ray McGovern, no Trump partisan, has been blacklisted by much of the progressive media (which once loved him) because he won’t go along with the Russiagate story, and he sharply dissents about the significance of the memo as well.

https://youtu.be/ifCuUO3scjY?t=31

It was Purdue Pharma that stated it would reduce its production. (How could I forget that? They are a major producer of of Oxycontin.)

https://www.statnews.com/2017/12/18/prescription-drug-supply-dea/

Martin Armstrong Asks “Is George Soros One Of The Greatest Threats Against Society?”

“I personally believe he is very dangerous politically… he stands for control of the people and is always plotting for the manipulation of society…”

https://www.zerohedge.com/news/2018-02-09/martin-armstrong-asks-george-soros-one-greatest-threats-against-society

Meanwhile in Silicon Valley, hoping to become the Amazon of Financial Services:
https://www.robinhood.com/

They call themselves, “stockbrokers for the 99%”

already more members than ETrade, they claim.
Also allowing direct purchase of cryptos!

NOT an endorsement by me; just info.

Also:

https://crypto.robinhood.com/

The miners look like they are in for some significant relief next week:

http://stockcharts.com/h-sc/ui?s=GDX&p=W&yr=3&mn=0&dy=9&id=p14940025933&a=576891465

Meanwhile in Syria, Israeli plane shot down by Iranian missile.

http://www.bbc.com/news/world-middle-east-43014081

GDXJ precisely followed a Fibonacci arc as it fell for the last two weeks and is clearly due for a tradable bounce (at least)…

2 hour chart:
http://stockcharts.com/h-sc/ui?s=GDXJ&p=120&yr=0&mn=5&dy=19&id=p22025353121&a=574289025

News:
https://www.youtube.com/watch?v=yAbK23RiSxY

(ANX) (ANXGD) Anaconda Scores 34.7 g/t Gold over 3.5 Meters

Bob Moriarty of 321 Gold looks at this gold explorer’s drill results for its Nova Scotia project.

https://www.streetwisereports.com/article/2018/02/07/anaconda-scores-34-7-g-t-gold-over-3-5-meters.html

You want to know why Michelle Obama will NOT run for President?
A tax cheat.

https://www.usapoliticstoday.com/michelle-obama-register-run-president-denied/

i’m beginning to think some reporters read this blog!

NEW YORK (AP) — The maker of the powerful painkiller OxyContin said it will stop marketing opioid drugs to doctors, bowing to a key demand of lawsuits that blame the company for helping trigger the current drug abuse epidemic.

OxyContin has long been the world’s top-selling opioid painkiller, bringing in billions in sales for privately-held Purdue, which also sells a newer and longer-lasting opioid drug called Hysingla.

The company announced its surprise reversal on Saturday. Purdue’s statement said it eliminated more than half its sales staff this week and will no longer send sales representatives to doctors’ offices to discuss opioid drugs. Its remaining sales staff of about 200 will focus on other medications.

The OxyContin pill, a time-release version of oxycodone, was hailed as a breakthrough treatment for chronic pain when it was approved in late 1995. It worked over 12 hours to maintain a steady level of oxycodone in patients suffering from a wide range of pain ailments. But some users quickly discovered they could get a heroin-like high by crushing the pills and snorting or injecting the entire dose at once. In 2010 Purdue reformulated OxyContin to make it harder to crush and stopped selling the original form of the drug.

Purdue eventually acknowledged that its promotions exaggerated the drug’s safety and minimized the risks of addiction. After federal investigations, the company and three executives pleaded guilty in 2007 and agreed to pay more than $600 million for misleading the public about the risks of OxyContin. But the drug continued to rack up blockbuster sales.

Dr. Andrew Kolodny, director of opioid policy research at Brandeis University and an advocate for stronger regulation of opioid drug companies, said Purdue’s decision is helpful, but it won’t make a major difference unless other opioid drug companies do the same.

“It is difficult to promote more cautious prescribing to the medical community because opioid manufacturers promote opioid use,” he said.

Allergan, which makes three opioid pain medications, said it has not actively marketed those drugs in years, and Janssen Pharmaceuticals, a unit of Johnson & Johnson, said it stopped marketing the medications in 2015. Both said opioid drugs make up a very small portion of their total revenue. Another drugmaker, Insys, said it was not able to comment immediately, while Teva Pharmaceutical Industries did not immediately respond to a request for comment.

Kolodny said that opioids are useful for cancer patients who are suffering from severe pain, and for people who only need a pain medication for a few days. But he said the companies have promoted them as a treatment for chronic pain, where they are more harmful and less helpful, because it’s more profitable.

“They are still doing this abroad,” Kolodny added. “They are following the same playbook that they used in the United States.”

Purdue Pharma only does business in the U.S. It is associated with two other companies, Mundipharma and Napp, that operate in other countries. It said those companies have separate leadership and operate according to local regulations.

Purdue and other opioid drugmakers and pharmaceutical distributors continue defending themselves against hundreds of local and state lawsuits seeking to hold the industry accountable for the drug overdose epidemic. The lawsuits say drugmakers misled doctors and patients about the risks of opioids by enlisting “front groups” and “key opinion leaders” who oversold the drugs’ benefits and encouraged overprescribing. State and local governments are seeking money and changes to how the industry operates, including an end to the use of outside groups to push their drugs.

Kolodny is serving as an expert advising the court in those lawsuits.

U.S. deaths linked to opioids have quadrupled since 2000 to roughly 42,000 in 2016, or about 115 lives lost per day. Although initially driven by prescription drugs, most opioid deaths now involve illicit drugs, including heroin and fentanyl.

By MENELAOS HADJICOSTIS – Associated Press – Sat Feb 10, 2:49PM CST
NICOSIA, Cyprus (AP) — Turkish warships on maneuvers in the Mediterranean Sea have blocked a rig belonging to the Italian energy firm ENI from reaching an area off Cyprus to start searching for gas, officials said Saturday.

Cyprus’ Foreign Minister Ioannis Kasoulides told state broadcaster RIK that the rig has halted its journey heading south of Cyprus and was waiting for directions from ENI. He says Cypriot authorities are in contact with the company and the Italian government.

The Saipem 12000 rig was stopped Friday by Turkish military ships and told not to continue “because there would be military activities in the destination area,” an ENI spokesman told The Associated Press. “The vessel has prudently executed the orders and will remain in position pending a development of the situation.”

The ENI official spoke on condition of anonymity in line with company policy.

The rig was on its way to drill an exploratory well at Block 3, an area southeast of the island nation, where ENI is licensed to search for hydrocarbons beneath the seabed.

On Thursday, Cyprus said ENI and partner TOTAL of France had discovered a potentially sizeable gas deposit at another block south of the island.

WASHINGTON (AP) — President Donald Trump makes big promises to reduce prescription drug costs, but his administration is gravitating to relatively modest steps such as letting Medicare patients share in manufacturer rebates.

Those ideas would represent tangible change and they have a realistic chance of being enacted. But it’s not like calling for Medicare to negotiate drug prices.

Skeptics say the overall approach is underwhelming, and Trump risks being seen as an ally of the powerful pharmaceutical industry, not its disrupter.

The White House Council of Economic Advisers has released a 30-page strategy for reducing drug costs, and it calls current policies “neither wise nor just.” The plan, outlined before Trump releases his new budget proposal Monday, focuses mainly on Medicare and Medicaid changes, along with ideas for speeding drug approvals and fostering competition.

“Despite promises to drastically lower prices the mix of proposed changes does not appear likely to do so, even though there are some constructive proposals,” said John Rother, CEO of the National Coalition on Health Care, an advocacy group whose members include consumer organizations, medical societies, hospitals and insurers.

Polls show the high cost of drugs is a top concern of Americans, regardless of political leanings. In his State of the Union speech, Trump seemed to foreshadow major change, saying “fixing the injustice of high drug prices” is a top priority this year.

“And prices will come down substantially,” Trump added. “Watch.”

As a candidate, Trump advocated Medicare negotiations and he called for allowing consumers to import lower-priced medicines from abroad. But the White House strategy paper veers away from such dramatic steps. His new health secretary, Alex Azar, was a top executive at pharmaceutical giant Eli Lilly.

Medicare negotiations and drug importation are unacceptable to the drug industry, which has spent tens of millions of dollars since Trump’s inauguration to influence the Washington conversation around drug prices, including a high-profile TV advertising campaign portraying its scientists as medical trailblazers.

The White House strategy largely sidesteps the question of whether drugmakers set their prices too high to start with. Rather, it recommends changes to policies that the administration believes unwittingly lead to higher prices, and suggests ways to speed drugs to market and increase competition.

It takes aim at foreign governments that dictate what drug companies can charge their own citizens. Trump often has noted that the same medications Americans struggle to pay for can be bought for much less abroad. The White House report examined 35 economically advanced countries, and found that U.S. consumers and taxpayers pay for more than 70 percent of drug company profits that fund innovation.

“Other nations are free-riding, or taking unfair advantage,” according to the review.

The industry defends its pricing by saying companies have to recoup considerable research and drug development costs within the limited window when brand drugs are protected from generic competition. But examples of profit-seeking abound.

An investigation by Sens. Charles Grassley, R-Iowa, and Ron Wyden, D-Ore., in 2015 found that the makers of the breakthrough hepatitis C drug Sovaldi decided to charge roughly $1,000 per pill even though the company’s own analysis showed a lower price would allow more patients to be treated. Gilead Sciences disagreed with the senators’ conclusion that it put profits before patients.

The White House strategy recommends:

—working with states to revise Medicaid rules so manufacturers don’t have an incentive to set artificially high prices due to the rebates they provide the program for low-income people.

—changing the way Medicare pays for drugs administered in a doctor’s office so Medicare doesn’t reimburse based on a fixed percentage of a drug’s cost. Critics say the current system creates an incentive for doctors to prescribe more expensive medications. The Obama administration proposed a similar change, but had to back off.

—changing a requirement that insurers in Medicare’s prescription program cover at least two different medications in each broad class of drugs. In some cases, that can tie the hands of insurers trying to negotiate lower prices.

—requiring insurers to share rebates from drug companies with patients. Drugmakers use the rebates to help gain market share. Insurers say they plow the money into reducing premiums. But patient copayments are usually based on the full price of the drug, before rebates. The issue is a major source of friction between drug companies and insurers.

—revising the Food and Drug Administration’s drug review and approval process to promote competition.

Many of the ideas can be pursued by the administration through rule-making, which means Trump can drive change without a balky Congress. But whether that translates into a big hit with the public is unclear. There’s no estimate from the White House of the potential impact on prices.

Financial analyst and former drug company executive Richard Evans said the administration plan would help bring down costs, but not to the same degree as giving Medicare a direct role in setting prices.

AK-47 Rifles, Claymore Mines, & Grenade Launchers Discovered On Mexico Border

The federal government of Mexico recently deployed thousands of Mexican soldiers, Marines, and police officers to the Gulf region of the Mexico-United States border, as drug cartel violence spirals out of control.

https://www.zerohedge.com/news/2018-02-10/ak-47-rifles-claymore-mines-grenade-launchers-discovered-mexico-border

Nenner on Hunter:

https://www.youtube.com/watch?v=vsXxG6uxpOY

I’m leaving to go off to Europe for awhile in a little over a fortnight.
Can we please settle this gold bull before I go ?
I’m loaded up at present but still have plenty of dry powder.
Looking at the price of Miners on the internet isn’t what I’m going there for to decide when to add some more.
But whats the bet I will be.
If your in Italy, Belgium, France or England then look out for us,
We’ll be the Clan at this family reunion who eats everything & attempts to drink everyplace dry.
Cheers.

The Transitional Flight to Quality – Martin Armstrong

QUESTION: Hey Martin, … My question is: is there an influence of the Dow at this moment on the cryptocurrency market and the precious metal market? As you say, gold is not ready yet… Will the possible correction of the Dow play the confidence game and scare a lot of markets off?

ANSWER: Yes. With Dow declining, we are failing to see a rally in cryptocurrency or gold and the long-touted flight to quality is not unfolding as most have expected.

When Equities typically decline, people run to the government bonds, and this we call the Flight to Quality. Others have touted that gold would soar when the stock market crashes. That too has not unfolded. Others have forecast that the dollar will collapse when the stock market crashes. Hm, even the Euro has declined.

What nobody seems to be talking about is what happens when the crisis is confined to government? Is that when gold rises? But then what about stocks? When CONFIDENCE collapses in government, the Flight to Quality becomes the opposite of tradition sell equities and buy bonds. Even when gold was rising moving up into 1980, bonds were declining.

So what is going on this time? We are in the midst of the Transition from the confidence in government to the private sector but nobody seems to understand what is unfolding. This is why we are getting mixed signals and strange relationships.

People will invest in the private sector and sell government bonds, smelling a default in the wind.We are more than likely going to get the first kneejerk reaction, where equities will DECLINE and people will rush into government bonds, even with negative yields. This should create the final bubble top in debt, and then it will reverse in a Flash Crash type move. Traditional people will buy bonds and lose a fortune. Others will sell their stocks at the lows and jump on short positions. This will set the stage for a crazy period that comes around every so often, measured in hundreds of years.

https://www.armstrongeconomics.com/armstrongeconomics101/economics/the-transitional-flight-to-quality/

EX!
FullGoldCrown
just gave Graddhy the boot over at GoldTentParadise!!! WHY? Was he too self promoting? Either way, he seemed to have some solid charting abilities!

The miners have been trapped in a box for the last year:

http://stockcharts.com/h-sc/ui?s=%24GDM&p=D&yr=1&mn=3&dy=0&id=p13338042418&a=577064562

Interesting GDX:GLD weekly chart:

http://stockcharts.com/h-sc/ui?s=GDX%3AGLD&p=W&yr=3&mn=9&dy=0&id=p15825612404&a=576996936

Zerohedge is been hit again, various stories are not downloading.

Marijuana Tops Liquor Sales For First Time In Aspen

Fri, 02/09/2018

“Marijuana shops in Aspen raked in the green in 2017, topping liquor sales with $11.3 million in revenue vs. $10.5 million of alcohol in the Colorado resort town home to just under 7,000 residents, and tens of thousands of tourists who are more mellow than ever.”

https://www.zerohedge.com/news/2018-02-09/marijuana-tops-liquor-sales-first-time-aspen

As I have said over and over….MA writes it well.
https://www.armstrongeconomics.com/armstrongeconomics101/economics/the-transitional-flight-to-quality/

CSIRO AND ARTEMIS TO INVESTIGATE CONGLOMERATE HOSTED GOLD -KARRATHA, WESTERN AUSTRALIA

https://www.asx.com.au/asxpdf/20180212/pdf/43rhdg7wtqv3cq.pdf

JEROME CORSI Q-Anon ANALYSIS 2-11-18 (PT-1) SUBSCRIBE 4 UPDATES (CBTS PATRIOTS) BREAKING NEWS!

https://www.youtube.com/watch?v=TmNVRxAEaGk

(RPM) (RPMGF) Rye Patch Gold Hires Chief Operating Officer

@newswire on February 12, 2018

https://ceo.ca/@newswire/rye-patch-gold-hires-chief-operating-officer

Avi Gilburt made the point about some of the larger laggards like Barrick being the reason for the drag down in GDX pricing, and that he had a number of stocks that were doing far better than the GDX share price.

I completely agree, and this is why picking the higher performance Jrs will always outperform the slow and clunky Srs. For an investor that doesn’t want to do any homework the ETFs are nice enough, but it can be far more rewarding for investors to just build their own Gold or Silver ETFs and pick the higher torque and higher leveraged Jrs to achieve the outperformance people are attracted to in the mining sector.

__________________________________________________________

Gold Giant Barrick Faces Grilling After Fall to Bottom of Pack

By Danielle Bochove – February 11, 2018

“Barrick Gold Corp. executives will have some explaining to do when the company releases full-year results Wednesday.”

“Even with rising gold prices and a strengthened balance sheet, the world’s largest gold producer left shareholders with the worst returns among its top North American peers last year and the third-worst performance in the 15-company BI Global Senior Gold Valuation Peers index.”

https://www.bloomberg.com/news/articles/2018-02-12/gold-giant-to-face-grilling-after-comparative-2017-share-wreck

Mining Stocks – When You Feel Good, Sell (Something)
by FI FIGHTER on FEBRUARY 12, 2018

“Mining stocks are an extremely volatile asset class where the odds of any investor getting into a story, experiencing impressive gains, only to then take a round trip back to break-even… and finally into NEGATIVE territory are actually quite high (sadly)… In fact, that dreaded rollercoaster ride where you see all your once “hefty” profits in any single position later eviscerated into NOTHING is something that I’ve experienced more often than I’d like to admit…”

“Yes, it’s impossible to ever perfectly “time the market”, but I think it goes without saying with mining stocks — Whenever you’re in healthy profits and feeling good about yourself, it’s a prudent idea to consider booking some profits!”

“Now, the key word here is “some”… For each investor, it’ll vary… Perhaps, you might consider “selling 1/2 on a double”, or start trimming down some stock in tranches… In the most extreme cases (these are actually my favorite scenarios), you’ll be very open and honest with yourself and declare most adamantly that you’ve had a spectacular run and it’s now worthwhile to close out the entire position and call it a day…”

http://fifighter.com/mining-stocks/2018/02/mining-stocks-when-you-feel-good-sell-something/

Silver is up over 2% today and many of the miners are up 2-3 times that.

Impact Silver – A Proven Silver Producer With A Higher Ceiling

https://seekingalpha.com/article/4145099-impact-silver-proven-silver-producer-higher-ceiling